SAGE Therapeutics (SAGE) 'Hits It Out of the Park' with SAGE-217 Data - Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sage Therapeutics to Provide Update on Key 2019 Initiatives at J.P. Morgan Healthcare Conference
January 7, 2019 7:00 AM ESTMulti-franchise strategy ongoing in depression, neurology and neuropsychiatry
Commercial infrastructure build completed for ZULRESSO (brexanolone) injection ahead of March 19, 2019 target PDUFA date
Statistically significant results achieved in Phase 3 trial of SAGE-217 in postpartum depression
First patient dosed in second pivotal trial of SAGE-217 in major depressive disorder
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Chief Executive Officer,... More
Sage Therapeutics Announces SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression
January 7, 2019 6:00 AM ESTStatistically significant reduction observed in depressive symptoms compared to placebo in women with postpartum depression (PPD)
Well-tolerated with rapid onset of statistically significant effect (Day 3) through two weeks and maintained for four weeks after treatment
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported top-line results from the Phase 3 ROBIN Study. This study evaluated the effect of SAGE-217 30 mg on depressive symptoms in women with postpartum depression (PPD). After two weeks of outpatient... More
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 4, 2019 6:30 AM ESTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics(NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2019, the Compensation Committee of Sages Board of Directors granted non-qualified stock options to purchase an aggregate of 15,000 shares of its common stock to five new employees under Sages 2016 Inducement Equity Plan.
The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee... More
